GORDON CARL L — SEC insider filings
SEC reporting owner CIK 1282930. 81 insider filings on record with FilingPulse; latest filed 2026-11-10.
Transaction summary — filings shown
Covers the 50 most recent of 81 filings on record, filed 2022-06-21 to 2026-11-10. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 61 legs across 19 filings — 17,974,099 shares, $118,378,867 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 10 legs across 4 filings — 3,901,936 shares, $17,251,990 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 117.
- Largest priced transaction: purchase of 1,000,000 shares @ $15.00 ($15,000,000) in Electra Therapeutics, Inc., filed 2026-09-23.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Electra Therapeutics, Inc. (ETRA) | Director, 10% owner | 3 | 18 legs · 1,898,020 sh · $24,349,642 | — | 8 |
| ADARx Pharmaceuticals, Inc. (ADRX) | Director, 10% owner | 2 | 3 legs · 950,000 sh · $16,150,000 | — | 16 |
| Scribe Therapeutics, Inc. (SCTX) | Director | 2 | 1 leg · 1,000,000 sh · $15,000,000 | — | 3 |
| MBX Biosciences, Inc. (MBX) | Director, 10% owner | 3 | 6 legs · 940,672 sh · $14,020,756 | — | 6 |
| Keros Therapeutics, Inc. (KROS) | Director | 5 | — | 2 legs · 250,000 sh · $11,002,500 | 6 |
| Terns Pharmaceuticals, Inc. (TERN) | Director, 10% owner | 7 | 4 legs · 3,827,931 sh · $9,929,800 | 6 legs · 56,164 sh · $561,640 | 7 |
| BlossomHill Therapeutics, Inc. (BLSM) | Director | 2 | 1 leg · 625,000 sh · $10,000,000 | — | 5 |
| Adicet Bio, Inc. (ACET) | Director, 10% owner | 6 | 7 legs · 4,000,000 sh · $9,328,750 | — | 20 |
| ArriVent Biopharma, Inc. (AVBP) | Director, 10% owner | 1 | 2 legs · 444,444 sh · $7,999,992 | — | 8 |
| Kinnate Biopharma Inc. (KNTE) | Director, 10% owner | 5 | 14 legs · 2,866,100 sh · $7,760,135 | — | 11 |
+4 more issuers among the filings shown — every filing appears in the table below.
Insider filings — GORDON CARL L
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-10 | 4 | Electra Therapeutics, Inc. (ETRA) | Purchase (P): 9,816 @ $7.85 · Purchase (P): 39,600 @ $7.85 · Purchase (P): 4,000 @ $8.24 · Purchase (P): 16,000 @ $8.24 · Purchase (P): 20,700 @ $8.45 · Purchase (P): 2,000 @ $8.45 | EDGAR |
| 2026-11-05 | 4 | Electra Therapeutics, Inc. (ETRA) | Purchase (P): 24,313 @ $7.84 · Purchase (P): 97,800 @ $7.84 · Purchase (P): 24,400 @ $7.88 · Purchase (P): 98,600 @ $7.88 · Purchase (P): 9,267 @ $7.78 · Purchase (P): 37,100 @ $7.78 · +4 more | EDGAR |
| 2026-09-30 | 4 | ADARx Pharmaceuticals, Inc. (ADRX) | Conversion (C): 10,690,530 · Conversion (C): 2,000,962 · Conversion (C): 769,601 · Conversion (C): 564,187 · Purchase (P): 300,249 @ $17 · Conversion (C): 7,127,019 · +13 more | EDGAR |
| 2026-09-24 | 3 | ADARx Pharmaceuticals, Inc. (ADRX) | Holdings only — no transactions reported | EDGAR |
| 2026-09-23 | 4 | Electra Therapeutics, Inc. (ETRA) | Conversion (C): 2,002,310 · Conversion (C): 1,087,934 · Conversion (C): 1,703,314 · Purchase (P): 333,333 @ $15 · Conversion (C): 758,279 · Purchase (P): 1,000,000 @ $15 · +4 more | EDGAR |
| 2026-08-12 | 4 | BlossomHill Therapeutics, Inc. (BLSM) | Conversion (C): 1,039,996 · Conversion (C): 1,049,283 · Purchase (P): 625,000 @ $16 · Conversion (C): 1,039,996 (derivative) @ $0 · Conversion (C): 1,049,283 (derivative) @ $0 | EDGAR |
| 2026-08-10 | 4 | BlossomHill Therapeutics, Inc. (BLSM) | Grant/award (A): 23,904 (derivative) @ $0 | EDGAR |
| 2026-07-29 | 4 | Scribe Therapeutics, Inc. (SCTX) | Conversion (C): 348,825 · Purchase (P): 1,000,000 @ $15 · Conversion (C): 2,065,672 (derivative) @ $0 | EDGAR |
| 2026-07-27 | 4 | Scribe Therapeutics, Inc. (SCTX) | Grant/award (A): 14,725 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Compass Therapeutics, Inc. (CMPX) | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Keros Therapeutics, Inc. (KROS) | Disposition to issuer (D): 140,057 @ $17.75 · Disposition to issuer (D): 74,465 @ $17.75 | EDGAR |
| 2025-06-06 | 4 | Keros Therapeutics, Inc. (KROS) | Grant/award (A): 5,250 @ $0 · Grant/award (A): 10,500 (derivative) @ $0 | EDGAR |
| 2025-04-11 | 4 | Compass Therapeutics, Inc. (CMPX) | Sale (S): 3,571,428 @ $1.59 | EDGAR |
| 2025-02-19 | 4 | MBX Biosciences, Inc. (MBX) | Purchase (P): 17,962 @ $9.90 · Purchase (P): 29,540 @ $9.85 · Purchase (P): 49,070 @ $10.84 · Purchase (P): 94,100 @ $10.84 | EDGAR |
| 2025-02-13 | 4 | Compass Therapeutics, Inc. (CMPX) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-11-05 | 4 | Lomond Therapeutics Holdings, Inc. | Conversion (C): 323,916 @ $3.20 · Conversion (C): 215,146 @ $3.20 · Conversion (C): 389,078 @ $3.60 · Conversion (C): 230,753 @ $3.60 · Conversion (C): 74,613 @ $3.60 · Grant/award (A): 808,894 @ $4 · +7 more | EDGAR |
| 2024-09-17 | 4 | MBX Biosciences, Inc. (MBX) | Conversion (C): 2,658,428 · Conversion (C): 403,787 · Purchase (P): 500,000 @ $16 · Purchase (P): 250,000 @ $16 · Conversion (C): 12,372,634 (derivative) · Conversion (C): 19,587,284 (derivative) · +1 more | EDGAR |
| 2024-09-13 | 4 | MBX Biosciences, Inc. (MBX) | Grant/award (A): 15,963 (derivative) @ $0 | EDGAR |
| 2024-08-23 | 4 | Adicet Bio, Inc. (ACET) | Disposition to issuer (D): 30,000 (derivative) @ $0 · Grant/award (A): 30,000 (derivative) @ $0 · Disposition to issuer (D): 18,500 (derivative) @ $0 · Grant/award (A): 18,500 (derivative) @ $0 · Disposition to issuer (D): 18,500 (derivative) @ $0 · Grant/award (A): 18,500 (derivative) @ $0 · +2 more | EDGAR |
| 2024-08-15 | 4 | Keros Therapeutics, Inc. (KROS) | Sale (S): 220,600 @ $44.01 · Sale (S): 29,400 @ $44.01 | EDGAR |
| 2024-07-17 | 4 | Terns Pharmaceuticals, Inc. (TERN) | Sale (S): 39,433 @ $10 · Sale (S): 5,401 @ $10 · Sale (S): 6,142 @ $10 · Sale (S): 4,009 @ $10 · Sale (S): 556 @ $10 · Sale (S): 623 @ $10 | EDGAR |
| 2024-07-02 | 4 | Terns Pharmaceuticals, Inc. (TERN) | Grant/award (A): 4,676 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Terns Pharmaceuticals, Inc. (TERN) | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Adicet Bio, Inc. (ACET) | Grant/award (A): 5,900 @ $0 · Grant/award (A): 26,400 (derivative) @ $0 | EDGAR |
| 2024-06-03 | 4 | Keros Therapeutics, Inc. (KROS) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2024-05-20 | 4 | BiomX Inc. (PHGE) jointly with OrbiMed Israel BioFund GP Limited Partnership, OrbiMed Israel GP Ltd., Chimovits Erez | Option exercise/expiry (X): 9,280,408 @ $0.24 · Sale (S): 24,344 @ $0.38 · Option exercise/expiry (X): 9,280,408 (derivative) @ $0 | EDGAR |
| 2024-04-05 | 4 | Kinnate Biopharma Inc. (KNTE) | Disposition to issuer (D): 1,368,339 · Disposition to issuer (D): 4,738,453 · Disposition to issuer (D): 1,368,338 · Disposition to issuer (D): 84,599 · Disposition to issuer (D): 450,000 · Disposition to issuer (D): 40,501 (derivative) · +2 more | EDGAR |
| 2024-03-19 | 4 | BiomX Inc. (PHGE) jointly with OrbiMed Israel BioFund GP Limited Partnership, OrbiMed Israel GP Ltd., Chimovits Erez | Purchase (P): 4,327 (derivative) · Purchase (P): 2,163,500 (derivative) | EDGAR |
| 2024-02-14 | 4 | Theseus Pharmaceuticals, Inc. (THRX) | Code (U): 17,063,000 · Code (U): 650,600 · Disposition to issuer (D): 3,250 (derivative) | EDGAR |
| 2024-02-14 | 4 | Compass Therapeutics, Inc. (CMPX) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | ArriVent Biopharma, Inc. (AVBP) | Conversion (C): 821,827 · Conversion (C): 821,827 · Conversion (C): 469,615 · Conversion (C): 469,615 · Purchase (P): 222,222 @ $18 · Purchase (P): 222,222 @ $18 · +4 more | EDGAR |
| 2024-01-26 | 4 | Adicet Bio, Inc. (ACET) | Purchase (P): 1,841,100 @ $2.40 · Purchase (P): 242,200 @ $2.40 · Purchase (P): 1,041,700 @ $2.40 | EDGAR |
| 2023-08-16 | 4 | Adicet Bio, Inc. (ACET) | Disposition to issuer (D): 30,000 (derivative) @ $0 · Grant/award (A): 30,000 (derivative) @ $0 · Disposition to issuer (D): 18,500 (derivative) @ $0 · Grant/award (A): 18,500 (derivative) @ $0 · Disposition to issuer (D): 18,500 (derivative) @ $0 · Grant/award (A): 18,500 (derivative) @ $0 · +2 more | EDGAR |
| 2023-07-19 | 4 | Theseus Pharmaceuticals, Inc. (THRX) | Purchase (P): 328,482 @ $3.05 · Purchase (P): 151,450 @ $3.05 | EDGAR |
| 2023-06-29 | 4 | Adicet Bio, Inc. (ACET) | Purchase (P): 125,000 @ $2.09 · Purchase (P): 250,000 @ $2.09 · Purchase (P): 442,000 @ $2.09 · Purchase (P): 58,000 @ $2.09 | EDGAR |
| 2023-06-14 | 4 | Terns Pharmaceuticals, Inc. (TERN) | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2023-06-13 | 4 | Kinnate Biopharma Inc. (KNTE) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2023-06-13 | 4 | Theseus Pharmaceuticals, Inc. (THRX) | Grant/award (A): 19,500 (derivative) @ $0 · Grant/award (A): 3,250 (derivative) @ $0 | EDGAR |
| 2023-06-08 | 4 | Keros Therapeutics, Inc. (KROS) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2023-06-02 | 4 | Adicet Bio, Inc. (ACET) | Grant/award (A): 5,900 @ $0 · Grant/award (A): 26,400 (derivative) @ $0 | EDGAR |
| 2023-05-08 | 4 | Kinnate Biopharma Inc. (KNTE) | Purchase (P): 83,459 @ $2.75 · Purchase (P): 312,991 @ $2.75 · Purchase (P): 83,459 @ $2.75 · Purchase (P): 490,512 @ $2.82 · Purchase (P): 490,511 @ $2.82 | EDGAR |
| 2023-05-02 | 4 | Kinnate Biopharma Inc. (KNTE) | Purchase (P): 60,998 @ $2.55 · Purchase (P): 228,754 @ $2.55 · Purchase (P): 60,997 @ $2.55 · Purchase (P): 124,544 @ $2.62 · Purchase (P): 467,068 @ $2.62 · Purchase (P): 124,545 @ $2.62 · +3 more | EDGAR |
| 2023-03-17 | 4 | BiomX Inc. (PHGE) jointly with OrbiMed Israel BioFund GP Limited Partnership, OrbiMed Israel GP Ltd., Chimovits Erez | Purchase (P): 348,000 @ $0.24 · Purchase (P): 1,789,959 (derivative) | EDGAR |
| 2023-02-22 | 4 | Kinnate Biopharma Inc. (KNTE) | Grant/award (A): 550,000 · Grant/award (A): 550,000 | EDGAR |
| 2023-02-09 | 4 | Compass Therapeutics, Inc. (CMPX) | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2022-12-28 | 4 | Terns Pharmaceuticals, Inc. (TERN) | Purchase (P): 137,931 @ $7.25 | EDGAR |
| 2022-11-10 | 4 | Compass Therapeutics, Inc. (CMPX) | Purchase (P): 402,000 @ $3.21 | EDGAR |
| 2022-11-09 | 4 | Theseus Pharmaceuticals, Inc. (THRX) | Purchase (P): 192,000 @ $5.21 | EDGAR |
| 2022-08-18 | 4 | Terns Pharmaceuticals, Inc. (TERN) | Purchase (P): 2,470,200 @ $2.42 · Purchase (P): 457,400 @ $2.42 · Purchase (P): 762,400 @ $2.42 · Purchase (P): 207,500 (derivative) · Purchase (P): 38,450 (derivative) · Purchase (P): 64,050 (derivative) | EDGAR |
| 2022-06-21 | 4 | Terns Pharmaceuticals, Inc. (TERN) | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-16 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1282930 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs